Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bis

A post hoc analysis was performed combining the data from two previously conducted randomized controlled trials (RCTs) in postmenopausal women (total of 1705 patients) with low adherence to a daily/weekly BP treatment who then transitioned to either denosumab or a monthly BP treatment (ibandronate and risedronate, respectively). This study aimed to compare bone mineral density and bone turnover marker levels. Results indicated that patients in the denosumab group were associated with significantly greater increases in bone mineral density at the total hip, femoral neck, and lumbar spine at 12 months, and significantly greater decreases in sCTX-1 levels from baseline compared to bisphosphonate treatments. Similar trends were observed for subgroups of patients with a higher risk for fracture and lower risk of fracture, respectively. Frequency of adverse events were similar between groups.